Saturday, October 31, 2026

GBP/EUR Bullish Momentum With A 1% Jump In The Last 10 Sessions

ViaNews Editorial Team

November 30, 2023

GBP/EUR Bullish Momentum With A 1% Jump In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.05% for the last 10 sessions. At 18:09 EST on Thursday, 30 November, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 3.834% up from its 52-week low and 1.767% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.18%, 0.03%, and 0.20%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.18% (last week), 0.20% (last month), and 0.20% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy trying to stop the slide after three days of declines, sees 147.00 on Wednesday. According to FXStreet on Wednesday, 29 November, "The USD/JPY is pulling back towards the day's early bids near 147.50 as the US Dollar gets a choppy boost from better-than-expected US Gross Domestic Product (GDP) growth figures and a hawkish appearance from Federal Reserve (Fed) officials to balance out Tuesday's hawkish Fedpeak.", "The USD/JPY is seeing a light rebound after dipping below 147.00 in Wednesday's trading session, but upside momentum remains limited and it's getting difficult to ignore the fact that the US Dollar is down nearly 3.5% from multi-year peaks set in November just below the 152.00 major handle."
  • Usd/jpy dips below 147.40 as greenback gets punched lower by broad-market risk bid. According to FXStreet on Tuesday, 28 November, "The early week's near-term swing high into the 149.70 area sees the 50-day SMA now acting as technical resistance for immediate moves higher, and further downside will see the USD/JPY slipping into the chart territory below 147.00.", "The USD/JPY remains firmly well-bid in the long-term, trading under 3% back from the year's highs near 152.00, and the pair is still up almost 14% from 2023's lows near 127.20."
  • Usd/jpy trading into 147.00 ahead of Japan retail trade, China pmis loom over asia markets. According to FXStreet on Wednesday, 29 November, "The USD/JPY drifted lower in the back half of Wednesday's trading session after hitting an intraday peak just above 147.80. "
  • Usd/jpy to decline gradually from mid-2024 – HSBC. According to FXStreet on Wednesday, 29 November, "Looking to 2024, we think USD/JPY might not fall until rate cuts by the Fed look imminent, perhaps in the middle of the year.", "The anticipated policy contrast between the Fed easing and the BoJ normalising should allow USD/JPY to fall in a more sustainable way. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com